The biotechnology company receives a loan from the public promotional bank to drive a 3,500 m² facility that will increase its production capacity to meet the growing global demand for biological products. ICF Eurocrèdit loans offer advantageous conditions for Catalan SMEs thanks to co-financing from the European Union.
ICF has financed the new plant of the biotechnology company Leanbio in Sant Quirze del Vallès with a €4 million loan. The company, which specialises in the development and manufacturing of biological products for the pharmaceutical sector, is building new facilities that will expand its footprint from the current 400 m² at the Barcelona Science Park to 3,500 m².
The project, with a total investment of €25 million, will enable Leanbio to expand its production capacity and significantly reduce manufacturing time and costs in order to respond to the growing global demand for biological products. Construction works, which began in 2024, are expected to be completed in 2026.
The public banking financing is provided through an ICF Eurocrèdit loan, which offers advantageous conditions for Catalan SMEs seeking to boost investments, open new markets and develop innovative projects, thanks to co-financing from the European Union through the European Regional Development Fund (ERDF).
The new plant will house three production lines dedicated to the development and manufacturing of highly complex biological products, covering all stages from early development to advanced phases. The facilities will also include development laboratories, scale-up and quality control areas, and pilot production plants.
“Leanbio’s new plant is a strategic project for the country that strengthens our industrial and pharmaceutical sovereignty and consolidates Catalonia as a leading European biotechnology hub capable of generating innovation and opportunities, as well as attracting talent and investment,” said Vanessa Servera, CEO of ICF.
“The new plant in Sant Quirze del Vallès is a key investment to meet the growing global demand for biotechnology-based pharmaceutical products and to reinforce Leanbio’s industrial capabilities. The support of ICF, as the public promotional bank of the Generalitat de Catalunya, has been decisive in accelerating this project and enabling us to scale our activity with guarantees, quality and an international outlook,” said Albert Font, CEO of Leanbio.
The project has also been selected as an initiative under the PERTE for Vanguard Health, which aims to promote innovative technological projects in the pharmaceutical sector that also meet strict sustainability criteria.
